Document is current

Any future updates will be listed below

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients

Crossref DOI link: https://doi.org/10.1007/s10637-014-0125-2

Published Online: 2014-06-15

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark